Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 11
June 11 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Immune milestones to predict CMV after letermovir
Clinical Trials & Observations
J. S. Little,S. Prockop
View Articletitled, Immune milestones to predict CMV after letermovir
CAR-T for large B-cell lymphomas: the clock is ticking
Clinical Trials & Observations
Elise A. Chong
View Articletitled, CAR-T for large B-cell lymphomas: the clock is ticking

ADVANCES VIEWPOINT

Distinguishing ASH clinical practice guidelines from other forms of ASH clinical advice
Clinical Trials & Observations
Adam Cuker,Robert Kunkle,Rachel S. Bercovitz,Michael Byrne,Benjamin Djulbegovic,Sandra L. Haberichter,Jennifer Holter-Chakrabarty,Richard Lottenberg,Menaka Pai,Suely M. Rezende,Matthew D. Seftel,Roy L. Silverstein,Deirdra R. Terrell,Matthew C. Cheung
View Articletitled, Distinguishing ASH clinical practice guidelines from other forms of ASH clinical advice

REVIEW ARTICLE

Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications
Eric Letouzé,Philippe Moreau,Nikhil Munshi,Mehmet Samur,Stéphane Minvielle,Cyrille Touzeau
View Articletitled, Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications

CLINICAL TRIALS AND OBSERVATIONS

Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma
Clinical Trials & Observations
Owen A. O’Connor,Bor-Sheng Ko,Ming-Chung Wang,Dai Maruyama,Yuqin Song,Ee-Min Yeoh,Nick Manamley,Kensei Tobinai
View Articletitled, Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma
Supplemental data
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Clinical Trials & Observations
Marit Jalink,Chaja F. Jacobs,Jahanzaib Khwaja,Dorothea Evers,Coty Bruggeman,Bruno Fattizzo,Marc Michel,Etienne Crickx,Quentin A. Hill,Ulrich Jaeger,Arnon P. Kater,Anja B. U. Mäkelburg,Anouk Breedijk,Peter A. W. te Boekhorst,Marlijn P. A. Hoeks,Masja de Haas,Shirley D’Sa,Josephine M. I. Vos
View Articletitled, Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Supplemental data
Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia
Clinical Trials & Observations
Jennifer H. Han,Brandi Dupervil,Arash Mahajerin,Roshni Kulkarni,Marilyn Manco-Johnson,Courtney Thornburg
View Articletitled, Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
Clinical Trials & Observations
Régis Peffault de Latour,Morag Griffin,Richard J. Kelly,Jeff Szer,Carlos de Castro,Regina Horneff,Lisa Tan,Michael Yeh,Jens Panse
View Articletitled, Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
Supplemental data
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A
Clinical Trials & Observations
Frank M. Horling,Birgit M. Reipert,Peter Allacher,Werner Engl,Luying Pan,Srilatha Tangada
View Articletitled, Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A
Supplemental data
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
Clinical Trials & Observations
Julia Driessen,Fer de Wit,Alex F. Herrera,Pier Luigi Zinzani,Ann S. LaCasce,Peter D. Cole,Craig H. Moskowitz,Ramón García-Sanz,Michael Fuchs,Horst Müller,Peter Borchmann,Armando Santoro,Heiko Schöder,Josée M. Zijlstra,Barbara A. Hutten,Alison J. Moskowitz,Marie José Kersten
View Articletitled, Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
Supplemental data
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
Clinical Trials & Observations
Satheesh Chonat,Alexander Kulagin,Alexey Maschan,Marije Bartels,Jochen Buechner,Rowena Punzalan,Michael Richards,Masayo Ogawa,Eden Hicks,Ji Yu,André Baruchel,Austin G. Kulasekararaj
View Articletitled, Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
Supplemental data
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Clinical Trials & Observations
Armin Ghobadi,Javier Munoz,Jason R. Westin,Frederick L. Locke,David B. Miklos,Aaron P. Rapoport,Miguel-Angel Perales,Patrick M. Reagan,Joseph McGuirk,Caron A. Jacobson,Marie José Kersten,Irit Avivi,Andrew Peng,Marco Schupp,Christina To,Olalekan O. Oluwole
View Articletitled, Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Supplemental data

HEALTH SERVICES AND OUTCOMES

Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation
Warren B. Fingrut,Eric Davis,Anne Archer,Samantha Brown,Sean Devlin,Melissa Nhaissi,Candice Rapoport,Stephanie Chinapen,Amanda Kelly,Deborah Wells,Andromachi Scaradavou,Boglarka Gyurkocza,Esperanza Papadopoulos,Ioannis Politikos,Brian C. Shaffer,Juliet N. Barker
View Articletitled, Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation
Supplemental data

HEMATOPOIESIS AND STEM CELLS

A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis
Dang Nghiem Vo,Ouyang Yuan,Minoru Kanaya,Gladys Telliam-Dushime,Hongzhe Li,Olga Kotova,Emel Caglar,Kristian Honnens de Lichtenberg,Shamim Herbert Rahman,Shamit Soneji,Stefan Scheding,David Bryder,Karl-Johan Malmberg,Ewa Sitnicka
View Articletitled, A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy
Shanshan Guo,Wen Lei,Xueli Jin,Hui Liu,James Q. Wang,Wenhai Deng,Wenbin Qian
View Articletitled, CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy
Supplemental data
Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy
Huixiu Han,Lei Wang,Yuntian Ding,Brigitte Neuber,Angela Hückelhoven-Krauss,Min Lin,Hao Yao,Qian Chen,Tim Sauer,Maria-Luisa Schubert,Zhiqiang Guo,Carsten Müller-Tidow,Michael Schmitt,Anita Schmitt
View Articletitled, Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy
Supplemental data
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort
Shermarke Hassan,Guido Baselli,Luca Mollica,Riccardo L. Rossi,Himani Chand,Amal El-Beshlawy,Mohsen Elalfy,Vijay Ramanan,Peyman Eshghi,Mehran Karimi,Roberta Palla,Frits R. Rosendaal,Flora Peyvandi
View Articletitled, Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort
Supplemental data
PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation
Daniela Chmiest,Silvia Podavini,Kalliopi Ioannidou,David Vallois,Chantal Décaillet,Montserrat Gonzalez,Manfredo Quadroni,Kevin Blackney,Rebekka Schairer,Laurence de Leval,Margot Thome
View Articletitled, PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation
Supplemental data

LYMPHOID NEOPLASIA

Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL
Gaia Gentile,Teresa Poggio,Antonella Catalano,Minna Voutilainen,Mari Lahnalampi,Marta Andrade-Martinez,Tobias Ma,Roman Sankowski,Lina Goncharenko,Stefan Tholen,Kyuho Han,David W. Morgens,Marco Prinz,Michael Lübbert,Sophia Engel,Tanja Nicole Hartmann,Gunnar Cario,Martin Schrappe,Lennart Lenk,Martin Stanulla,Justus Duyster,Peter Bronsert,Michael C. Bassik,Michael L. Cleary,Oliver Schilling,Merja Heinäniemi,Jesús Duque-Afonso
View Articletitled, Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1<sup>+</sup>/preBCR<sup>+</sup> ALL
Supplemental data
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Clinical Trials & Observations
Adam S. Kittai,John N. Allan,Dan James,Helen Bridge,Miguel Miranda,Alan S. M. Yong,Fady Fam,Jack Roos,Vikram Shetty,Alan Skarbnik,Matthew S. Davids
View Articletitled, An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Supplemental data

MYELOID NEOPLASIA

Trajectories of physical well-being among adults with acute myeloid leukemia
Marielle Jensen-Battaglia,Michael B. Sohn,William Consagra,Ying Wang,Zhihong Zhang,Marissa LoCastro,Jenae Davis,Katheryn Buettner,Soroush Mortaz,Areej R. El-Jawahri,Kah Poh Loh
View Articletitled, Trajectories of physical well-being among adults with acute myeloid leukemia
Supplemental data
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
Alex Bataller,Georgina Gener-Ricos,Emmanuel Almanza-Huante,Kelly S. Chien,Samuel Urrutia,Alexandre Bazinet,Juan Jose Rodriguez-Sevilla,Danielle Hammond,Koji Sasaki,Koichi Takahashi,Courtney D. DiNardo,Farhad Ravandi,Gautam Borthakur,Tapan M. Kadia,Rashmi Kanagal-Shamanna,Hagop M. Kantarjian,Guillermo Garcia-Manero,Guillermo Montalban-Bravo
View Articletitled, Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
Supplemental data
Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation
Meenu Kesarwani,Zachary Kincaid,Mohammad Azhar,Mohammad Azam
View Articletitled, Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation
Supplemental data
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival
Shai Shimony,Julia Keating,Christopher J. Fay,Marlise R. Luskin,Donna S. Neuberg,Nicole R. LeBoeuf,Andrew A. Lane
View Articletitled, Organ involvement in adults with BPDCN is associated with sun exposure history, <em>TET2</em> and <em>RAS</em> mutations, and survival
Supplemental data
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Johannes Lübke,Alicia Schmid,Deborah Christen,Hanneke N. G. Oude Elberink,Lambert F. R. Span,Marek Niedoszytko,Aleksandra Gorska,Magdalena Lange,Karoline V. Gleixner,Emir Hadzijusufovic,Alex Stefan,Irena Angelova-Fischer,Roberta Zanotti,Massimiliano Bonifacio,Patrizia Bonadonna,Khalid Shoumariyeh,Nikolas von Bubnoff,Sabine Müller,Cecelia Perkins,Chiara Elena,Luca Malcovati,Hans Hagglund,Mattias Mattsson,Roberta Parente,Judit Varkonyi,Anna Belloni Fortina,Francesca Caroppo,Knut Brockow,Alexander Zink,Christine Breynaert,Toon Leven,Akif Selim Yavuz,Michael Doubek,Vito Sabato,Tanja Schug,Karin Hartmann,Massimo Triggiani,Jason Gotlib,Olivier Hermine,Michel Arock,Hanneke C. Kluin-Nelemans,Jens Panse,Wolfgang R. Sperr,Peter Valent,Andreas Reiter,Juliana Schwaab
View Articletitled, Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
Clinical Trials & Observations
Magdalena Kaczor,Stanislaw Malicki,Justyna Folkert,Ewelina Dobosz,Danuta Bryzek,Barbara Chruscicka-Smaga,Milena Greczan,Dorota Wesół- Kucharska,Barbara Piątosa,Emilia Samborowska,Joanna Madzio,Janusz Książyk,Ewa Ehmke vel Emczyńska,Małgorzata Hajdacka,Jan Potempa,Wojciech Młynarski,Dariusz Rokicki,Florian Veillard
View Articletitled, Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
Supplemental data

PLATELETS AND THROMBOPOIESIS

SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow
Isabelle Allaeys,Guillaume Lemaire,Mickaël Leclercq,Emile Lacasse,Maude Fleury,Isabelle Dubuc,Leslie Gudimard,Florian Puhm,Julia Tilburg,Andrew Stone,Kellie R. Machlus,Arnaud Droit,Louis Flamand,Eric Boilard
View Articletitled, SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow
Supplemental data
Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia
Henning Nilius,Hind Hamzeh-Cognasse,Janna Hastings,Jan-Dirk Studt,Dimitrios A. Tsakiris,Andreas Greinacher,Adriana Mendez,Adrian Schmidt,Walter A. Wuillemin,Bernhard Gerber,Prakash Vishnu,Lukas Graf,Johanna A. Kremer Hovinga,Tamam Bakchoul,Fabrice Cognasse,Michael Nagler
View Articletitled, Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Daniel Wang,Satoko Ito,Christina Waldron,Ayesha Butt,Ellen Zhang,Harlan M. Krumholz,Hanny Al-Samkari,George Goshua
View Articletitled, Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Supplemental data
Hemojuvelin-mediated hepcidin induction requires both bone morphogenetic protein type I receptors ALK2 and ALK3
Deniz Y. Dogan,Eugen I. Urzica,Isabelle Hornung,Philipp Kastl,David Oguama,Franca M. Fette,Lien H. Nguyen,Frank Rosenbauer,Kai Zacharowski,Ursula Klingmüller,Elise Gradhand,Andreas von Knethen,Rüdiger Popp,Ingrid Fleming,Lisa Schrader,Andrea U. Steinbicker
View Articletitled, Hemojuvelin-mediated hepcidin induction requires both bone morphogenetic protein type I receptors ALK2 and ALK3
Supplemental data

THROMBOSIS AND HEMOSTASIS

Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
Clinical Trials & Observations
Sara Arcudi,Roberta Gualtierotti,Erica Scalambrino,Marigrazia Clerici,Shermarke Hassan,Valentina Begnozzi,Elena Anna Boccalandro,Cristina Novembrino,Carla Valsecchi,Roberta Palla,Flora Peyvandi
View Articletitled, Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
Supplemental data
Fibrinogen levels and clot properties identify patients who benefit from catheter-directed thrombolysis after DVT
Clinical Trials & Observations
Aaron F. J. Iding,Ghadir Alkarithi,Hugo ten Cate,Robert A. S. Ariëns,Arina J. ten Cate-Hoek,and the CAVA trial investigators
View Articletitled, Fibrinogen levels and clot properties identify patients who benefit from catheter-directed thrombolysis after DVT
Supplemental data

TRANSFUSION MEDICINE

Machine learning to optimize automated RH genotyping using whole-exome sequencing data
Ti-Cheng Chang,Jing Yu,Zhaoming Wang,Jane S. Hankins,Mitchell J. Weiss,Gang Wu,Connie M. Westhoff,Stella T. Chou,Yan Zheng
View Articletitled, Machine learning to optimize automated <em>RH</em> genotyping using whole-exome sequencing data
Supplemental data

TRANSPLANTATION

Impaired T cells and “memory-like” NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation
Clinical Trials & Observations
Chris David Lauruschkat,Ihsan Muchsin,Alice Felicitas Rein,Florian Erhard,Denise Grathwohl,Lars Dölken,Carolin Köchel,Anne Nehmer,Christine Susanne Falk,Götz Ulrich Grigoleit,Hermann Einsele,Sebastian Wurster,Sabrina Kraus
View Articletitled, Impaired T cells and “memory-like” NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation
Supplemental data

VASCULAR BIOLOGY

Semaphorin 7A coordinates neutrophil response during pulmonary inflammation and sepsis
Tiago Granja,David Köhler,Linyan Tang,Philipp Burkard,Claudia Eggstein,Katherina Hemmen,Katrin G. Heinze,Ka-Lin Heck-Swain,Michael Koeppen,Sven Günther,Maximilian Blaha,Harry Magunia,Maximilian Bamberg,Franziska Konrad,Kristian-Christos Ngamsri,Anika Fuhr,Marius Keller,Alice M. Bernard,Helene A. Haeberle,Tamam Bakchoul,Alexander Zarbock,Bernhard Nieswandt,Peter Rosenberger
View Articletitled, Semaphorin 7A coordinates neutrophil response during pulmonary inflammation and sepsis
Supplemental data

RESEARCH LETTERS

Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia
Stien De Coninck,Juliette Roels,Béatrice Lintermans,Sara T’Sas,Tom Taghon,David J. Curtis,Tim Pieters,Steven Goossens,Pieter Van Vlierberghe
View Articletitled, <em>Tet2</em> is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia
Supplemental data
Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study
James S. Heald,Aleix Méndez López,Miguel L. Pato,Neus Ruiz-Xivillé,Marta Cabezón,Lurdes Zamora,Susana Vives,Rosa Coll,Clara Maluquer,Isabel Granada,Francesc Solé,Manel Esteller,María Berdasco
View Articletitled, Identification of novel <em>NUP98</em> fusion partners and comutations in acute myeloid leukemia: an adult cohort study
Supplemental data

ERRATUM

Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897.
View Articletitled, Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. <em>Blood Adv.</em> 2023;7(19):5890-5897.
  • Cover Image

    Cover Image

    issue cover

    Confocal microscopy image depicting the formation of neutrophil extracellular traps from patients with glycogen storage disease type 1b receiving empagliflozin treatment, displaying DNA in blue and neutrophil elastase in red. See the article by Kaczor et al.

All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals